Mostly Markets
Subscribe
Stocks/Health Care/Health Care Services

DaVitaDVA

Health Care Services · Denver, Colorado · In the S&P 500
Solid businessCheaper than peers
$187.50−3.01%After hours: $187.50 (0.00%)At the close, 30 Oct · Prices from CNBC, may be delayed
▲ 48.2% over 1 year
DaVita over 1 yearDaily close, $, to 30 Oct 2026
$100$150$200Nov2026MarMayJulSep$187.50$100$150$200NovMarJul$187.50
Source: Nasdaq daily closes
Market value$11.96B
Price to earnings14.2x
Forward P/E11.9x
Dividend yield–
Year to date+65.0%
One year+48.2%
Next earningsNot scheduled
SectorHealth Care
52-week range (closes)
$103.87$240.96

Quality and valuation

How DaVita compares with other health care stocks. A description, not a recommendation.

DaVita and 5 health care services peers. Across: valuation (P/E) against the sector. Up: business quality against the sector. Hover or tap a logo for its numbers.

Business quality: about averageValuation: cheaper than most

An average business among health care companies, priced below most of them.

DaVita trades at 11.9 times the next 12 months of expected earnings, against a median of 19.1x for the 65 health care stocks we cover. The quality score blends where it ranks on revenue growth, gross margin, operating margin and free-cash-flow margin (net margin for banks and insurers) over the last 12 months, from SEC filings.

  • Revenue grew slower than the sector median: +6.4% vs +7.8%
  • More profitable (operating margin): 15.0% vs 13.3%
  • Turns less of its sales into cash: 9.1% vs 15.9%
DVA trades at 11.9x forward earnings, below the sector medianForward p/e, Health Care Services peers
CI9.4xCVS11.1xDVA11.9xLH19.1xDGX22.2xHIMS73.4xSector median 19.1xCI9.4xCVS11.1xDVA11.9xLH19.1xDGX22.2xHIMS73.4xSector median 19.1x
Source: CNBC quotes; Mostly Markets
At 13.8x earnings, DVA is cheaper than its average since Oct 2024Price over the last 12 months of reported (GAAP) diluted EPS
P/EUsual range (±1 s.d.)
15x20xAverage 15.0x2025202613.8x15x20xAverage 15.0x2025202613.8x
Source: Nasdaq prices; SEC filings

Financials

From DaVita's SEC filings, through the quarter ending 30 Sep 2026. Hover or tap a bar for its value.

Revenue grew 4.6% from a year earlierQuarterly revenue, $bn, latest Q3 ’26
$0bn$1bn$2bn$3bnQ4 ’24Q2 ’25Q4 ’25$3.6bnQ3 ’26$0bn$2bnQ4 ’24Q2 ’25Q4 ’25$3.6bnQ3 ’26
Source: SEC filings
Growth slowed to +4.6% last quarterRevenue growth, year on year, %
0%2%5%8%Q4 ’24Q2 ’25Q4 ’254.6%Q3 ’260%5%Q4 ’24Q2 ’25Q4 ’254.6%Q3 ’26
Source: SEC filings
Operating margin was 14.0% last quarterOperating income as a share of revenue, %
0%5%10%15%Q4 ’24Q2 ’25Q4 ’2514.0%Q3 ’260%10%Q4 ’24Q2 ’25Q4 ’2514.0%Q3 ’26
Source: SEC filings
Free cash flow was $1.3 billion over 12 monthsQuarterly free cash flow (operating cash flow minus capex), $m
$0m$200m$400m$600mQ4 ’24Q2 ’25Q4 ’25$359mQ3 ’26$0m$250m$500mQ4 ’24Q2 ’25Q4 ’25$359mQ3 ’26
Source: SEC filings
Last 12 monthsDVASector median
Revenue growth+6.4%+7.8%
Operating margin15.0%13.3%
Free cash flow margin9.1%15.9%
Price to earnings14.2x30.2x

Stories on DaVita

We haven't written about DaVita yet. Follow it, and its first story will show under My stocks on the front page.

Similar companies

Health Care Services, by market value.

CompanyPriceTodayYTDValue
CVSCVS Health$90.25−0.09%+13.7%$115B
CICigna$298.23−0.06%+8.4%$78.80B
LHLabcorp$361.39−1.84%+44.0%$29.34B
DGXQuest Diagnostics$251.82−0.43%+45.1%$27.70B
HIMSHims & Hers Health$27.68−6.71%−14.8%$6.46B